TYK Medicines Inc. has announced its interim results for the six months ended June 30, 2025. The company reported no revenue or cost of sales for the period. The gross profit was impacted by other income and gains totaling a loss of RMB 20.82 million, compared to a loss of RMB 11.29 million during the same period in 2024. Research and development costs were reduced to RMB 88.76 million from RMB 137.76 million in 2024. Administrative expenses slightly decreased to RMB 38.78 million from RMB 40.10 million in the previous year. No dividends were paid or declared during this period. In terms of business operations, TYK Medicines Inc. highlighted significant progress with its core product, TY-9591. The company completed patient enrollment for a pivotal Phase II clinical trial of TY-9591 monotherapy in brain metastases from lung cancer with EGFR mutations, qualifying for conditional marketing.